Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
18 Fevereiro 2025 - 10:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February 2025
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
☐ No ☒
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”)
published one announcement (the “Public Notice”) to the Australian Securities Exchange on February 18, 2025 titled:
| - | “Participation
in B Riley Securities Radiopharma Conference” |
A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.
This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
EXHIBITS
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
RADIOPHARM THERANOSTICS LIMITED |
|
|
|
Date: February 18, 2025 |
By: |
/s/ Phillip
Hains |
|
|
Phillip Hains |
|
|
Company Secretary |
Exhibit
99.1
ASX ANNOUNCEMENT
18 FEBRUARY 2025 |
 |
RAD to
participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Sydney, Australia – 18 February 2025 – Radiopharm Theranostics (ASX:RAD, NASDAQ: RADX “Radiopharm” or the “Company”),
a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical
need, is pleased to announce that the Company will present at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference.
The event will be held on 28 February 2025 in New York, featuring more
than 35 small-to-mid cap public and private biopharma and med-tech companies focused on a range of life-saving therapies and imaging modalities.
A mix of institutional and professional investors will be in attendance,
with various fireside chats and key opinion leader discussions to take place, in addition to presentations from the participating companies
and individual investor meetings.
A copy of RAD’s presentation for the event will be released at
the time of the conference.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company
developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high
unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021 and on the Nasdaq (RADX) since November 2024. The company
has a deep pipeline of highly differentiated molecules spanning peptides, small molecules and monoclonal antibodies for use in cancer,
in pre-clinical and clinical stages of development. The pipeline has been built based on the potential to be first-to-market or best-in-class.
The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including brain, lung, breast
and pancreas. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm
Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics
Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Radiopharm Theranostics (PK) (USOTC:RDPTF)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Radiopharm Theranostics (PK) (USOTC:RDPTF)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025